| ABSTRACT Objective: To investigate the necessity of perioperative antifungal therapy for patients with chronic cavitary pulmonary aspergillosis (CCPA) according to the real clinical cases, and provide a reference for clinical treatment. Methods:A retrospective study of 34 CCPA patients who underwent operation between May 1, 2011 and June 30, 2018 was performed. 8 patients received antifungal therapy after the surgery，defined as group A. 26 patients were treated with surgery alone without antifungal therapy (group B). The improvement of clinical symptoms, blood routine, complications rate, recurrence rate and mortality were compared between the two groups. Results:There was no significant difference in preoperative condition from baseline of group A and B (P>0.05). But the pulmonary fuction of group B were better than the group A（P<0.05）. The symptom of hemoptysis was improved after surgery in both groups (Group A: P<0.05, Group B: P<0.01). While the improvement of clinical symptoms and blood routine were undifferentiated (P>0.05). The outcomes (complications rate, morbidity, mortality) between the two groups had not significant differences (P>0.05). Conclusion: Perioperative antifungal therapy had little benefit for patientis with CCPA. |
